Short answer
Medline Inc (MDLN) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 26, 2026. Quarterly revenue was $7.9B with net income of $194M.
Q3 2026 key financials · XBRL
- Revenue
- $7.9B
- +2.2% QoQ
- Net income
- $194M
- +198.5% QoQ
- Operating margin
- 6.4%
- Gross margin
- 24.5%
- EPS (diluted)
- $0.22
- +214.3% QoQ
Source: XBRL data from the Medline Inc (MDLN) Q3 2026 10-Q on SEC EDGAR. USD.
Medline Inc Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $7,856M, up 10.4% YoY from $7,115M, driven by organic volume growth
- Gross margin 24.5% vs 26.4% YoY; net income margin 4.0% vs 4.5%; Adjusted EBITDA margin 12.2% vs 12.1%
- Best segment: Medline Brand revenue $3,637M, up 6.6%, EBITDA margin 25.9% vs 24.1%; worst: Supply Chain Solutions margin 4.4% vs 5.5%
- Cash and equivalents $2,321M, short-term investments $1,287M; nine-month operating cash flow $2,152M vs $1,515M
- Headwinds: tariffs, FDA bed recall costs $60M to $210M, restructuring costs $20M to $30M; 2026 capital expenditures up to $600M
Risk Factors
- No material changes to risk factors disclosed in the 2025 Form 10-K
- Carried-forward risks remain unchanged for the quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.